Business Context and Reporting Period
Company: DarioHealth Corp. (DRIO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: DarioHealth is a global digital therapeutics (DTx) company providing a whole-person health platform addressing cardiometabolic (diabetes, hypertension, weight management), behavioral health (stress, anxiety, depression), and musculoskeletal conditions. The company serves employers, health plans, and pharmaceutical companies via a B2B2C model, alongside direct-to-consumer (D2C) offerings. A key strategic development in 2024 was the acquisition of Twill, Inc., a behavioral health technology company, to expand its multi-condition platform capabilities.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Total Revenues | $27,040 | $20,352 |
| Gross Profit | $13,267 | $5,984 |
| Gross Margin | 49.1% | 29.4% |
| Operating Loss | $(57,744) | $(56,189) |
| Net Loss | $(42,747) | $(59,427) |
| Cash and Cash Equivalents (Year End) | $27,764 | $36,797 |
| Accumulated Deficit | $(390,343) | $(349,361) |
| Long-Term Debt (Principal) | $28,923 | $28,545 |
Note: The Net Loss for 2024 was significantly reduced by a non-cash gain of approximately $16.3 million related to the revaluation of pre-funded warrant liabilities issued as part of the Twill acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32.9% year-over-year, driven primarily by the consolidation of Twill's revenues and growth in the commercial B2B2C channel. Pro forma revenue for 2024 (assuming Twill acquisition occurred Jan 1, 2023) would have been $29.0 million.
- Gross Margin Expansion: Gross margin improved from 29.4% to 49.1%. This was largely due to the shift toward higher-margin service revenues from Twill and a reduction in payroll-related expenses within the cost of revenues.
- Acquisition Impact: The acquisition of Twill on February 15, 2024, resulted in $15.8 million of goodwill and $19.4 million of identifiable intangible assets (technology and customer relationships). This increased amortization expenses but significantly expanded the product suite.
- Financial Income: Net financial expenses turned into net financial income of $13.1 million in 2024 (compared to $3.2 million expense in 2023), primarily due to the favorable revaluation of warrant liabilities.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management believes it has sufficient resources to fund operations through 2025 without raising additional capital, based on current cash on hand ($27.8 million) and anticipated revenue inflows. The company is focused on integrating Twill's behavioral health capabilities to create a comprehensive "whole-person" platform, aiming to drive top-line growth and operating efficiency. Strategic growth areas include GLP-1 medication support programs and expanding partnerships with employers and health plans.
Key Risks and Contingencies:
- Liquidity and Capital Requirements: The company has a history of losses and an accumulated deficit of $390 million. Continued profitability is not guaranteed, and future capital raises may be necessary, potentially causing dilution.
- Customer Concentration: As of December 31, 2024, one major customer accounted for 41.6% of accounts receivable and 24.6% of total revenue. Loss of this customer could materially impact results.
- Debt Covenants: The company has a $30 million credit facility with Avenue Venture Opportunities. The loan requires meeting specific milestones to extend interest-only periods and avoid principal amortization. Failure to meet these milestones could accelerate repayment obligations.
- Geopolitical Risk: Significant operations are located in Israel. Ongoing conflict and military instability in the region pose risks to operations, employee availability (reserve duty), and overall business continuity.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00) in September 2024. It has a compliance period until March 17, 2025, to regain compliance or face potential delisting.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $27.8 million cash balance against the projected burn rate and the ability to meet debt milestones without immediate equity dilution.
- Customer Concentration: Assess the stability of the contract with the major customer representing ~25% of revenue and ~42% of receivables.
- Debt Structure: Review the specific revenue and cash burn milestones required under the Avenue Loan Facility to avoid principal repayment acceleration.
- Stock Price Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by March 17, 2025, to avoid Nasdaq delisting.
- Non-GAAP Adjustments: Scrutinize the $16.3 million non-cash gain from warrant revaluation, which significantly masked the underlying operating loss for the year.